Safusidenib (AB-291, DS-1001) is an orally bioavailable, selective mutant IDH1 inhibitor. Safusidenib strongly inhibits mutant IDH1 but not wild-type IDH1. Safusidenib impairs tumor activity in chondrosarcoma[1]. Safusidenib exhibits activity against IDH1R132H, and IDH1R132C with IC50s of 15, and 130 nM in assays without any preincubation, respectively[2].
Molecular Weight:
535.78
Purity:
98.11
CAS Number:
[1898206-17-1]
Formula:
C25H18Cl3FN2O4
Target:
Isocitrate Dehydrogenase (IDH)
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
